O-GlcNAc modification of PPARγ reduces its transcriptional activity

被引:63
|
作者
Ji, Suena [2 ]
Park, Sang Yoon [2 ]
Roth, Juergen [3 ]
Kim, Hoe Suk [1 ]
Cho, Jin Won [2 ,3 ]
机构
[1] Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul 110744, South Korea
[2] Yonsei Univ, Dept Biol, Seoul 120749, South Korea
[3] Yonsei Univ, Grad Sch, Dept Integrated OMICS Biomed Sci, Seoul 120749, South Korea
基金
新加坡国家研究基金会;
关键词
O-GlcNAc; PPAR gamma; Adipogenesis; 3T3-L1; ACTIVATED RECEPTOR-GAMMA; N-ACETYLGLUCOSAMINE; C/EBP-ALPHA; INSULIN-RESISTANCE; MASS-SPECTROMETRY; GENE PROMOTER; ADIPOGENESIS; BETA; EXPRESSION; GLCNACYLATION;
D O I
10.1016/j.bbrc.2011.12.086
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The peroxisome proliferator-activated receptor gamma (PPAR gamma), a member of the nuclear receptor superfamily, is a key regulator of adipogenesis and is important for the homeostasis of the adipose tissue. The beta-O-linked N-acetylglucosamine (O-GlcNAc) modification, a posttranslational modification on various nuclear and cytoplasmic proteins, is involved in the regulation of protein function. Here, we report that PPAR gamma is modified by O-GIcNAc in 3T3-L1 adipocytes. Mass spectrometric analysis and mutant studies revealed that the threonine 54 of the N-terminal AF-1 domain of PPAR gamma is the major O-GlcNAc site. Transcriptional activity of wild type PPAR gamma was decreased 30% by treatment with the specific O-GlcNAcase (OGA) inhibitor, but the T54A mutant of PPAR gamma did not respond to inhibitor treatment. In 3T3-L1 cells, an increase in O-GlcNAc modification by OGA inhibitor reduced PPAR gamma transcriptional activity and terminal adipocyte differentiation. Our results suggest that the O-GlcNAc state of PPAR gamma influences its transcriptional activity and is involved in adipocyte differentiation. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:1158 / 1163
页数:6
相关论文
共 50 条
  • [21] Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody
    Yuzwa, Scott A.
    Yadav, Anuj K.
    Skorobogatko, Yuliya
    Clark, Thomas
    Vosseller, Keith
    Vocadlo, David J.
    AMINO ACIDS, 2011, 40 (03) : 857 - 868
  • [22] Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody
    Scott A. Yuzwa
    Anuj K. Yadav
    Yuliya Skorobogatko
    Thomas Clark
    Keith Vosseller
    David J. Vocadlo
    Amino Acids, 2011, 40 : 857 - 868
  • [23] Modulation of transcription factor function by O-GlcNAc modification
    Ozcan, Sabire
    Andrali, Sreenath S.
    Cantrell, Jamie E. L.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS, 2010, 1799 (5-6): : 353 - 364
  • [24] Regulation of autophagy: Insights into O-GlcNAc modification mechanisms
    Liu, Chengzhi
    Wang, Xinyu
    Xu, Shengnan
    Liu, Mingyue
    Cao, Xusheng
    LIFE SCIENCES, 2025, 369
  • [25] O-GlcNAc modification in diabetes and Alzheimer's disease
    Dias, Wagner B.
    Hart, Gerald W.
    MOLECULAR BIOSYSTEMS, 2007, 3 (11) : 766 - 772
  • [26] Specificity, function, and regulation of protein O-GlcNAc modification
    Jiang, Jiaoyang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [27] The potential role of O-GlcNAc modification in cancer epigenetics
    Ewa Forma
    Paweł Jóźwiak
    Magdalena Bryś
    Anna Krześlak
    Cellular & Molecular Biology Letters, 2014, 19 : 438 - 460
  • [28] Structural analyses of enzymes involved in the O-GlcNAc modification
    Martinez-Fleites, Carlos
    He, Yuan
    Davies, Gideon J.
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2010, 1800 (02): : 122 - 133
  • [29] O-GlcNAc: a regulatory post-translational modification
    Wells, L
    Whalen, SA
    Hart, GW
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2003, 302 (03) : 435 - 441
  • [30] O-GlcNAc modification, insulin signaling and diabetic complications
    Issad, T.
    Masson, E.
    Pagesy, P.
    DIABETES & METABOLISM, 2010, 36 (06) : 423 - 435